Zynext Ventures

Feldan Therapeutics specializes in intracellular drug delivery using its patented Feldan Shuttle technology. This platform enables rapid, safe, and efficient transport of therapeutic agents into cells, with a focus on developing treatments for serious diseases such as skin and lung conditions.

Illexcor Therapeutics is a biopharmaceutical company focused on developing innovative oral therapies for sickle cell disease. It specializes in creating Hemoglobin S polymerization inhibitors, aiming to provide significant clinical benefits and improve the lives of patients living with this condition.

Neuro42 specializes in the development and commercialization of advanced MRI and robotics technology aimed at improving the diagnosis and treatment of neurological conditions. The company designs portable magnetic resonance imaging machines that facilitate triaging, screening, diagnosing, and intervening in various brain disorders, including traumatic injuries, epilepsy, and tumors. By providing point-of-care solutions, Neuro42 enhances patient access to critical imaging and enables direct robotic interventions outside conventional MRI suites, particularly benefiting individuals who have experienced strokes. This innovative approach aims to streamline neurological care and improve patient outcomes through advanced imaging and intervention technologies.